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Risk of bone loss or fracture
among renal transplant
recipients: Race and steroid
To the Editor: In a recent issue of Kidney Interna-
tional, El-Agroudy et al suggested that early bone loss
that occurs during the first 12 months after renal trans-
plantation could be prevented by alfacalcidol, calcitonin,
or alendronate [1]. They enrolled 60 renal transplant
recipients, randomized into 4 groups (alfacalcidol, al-
endronate, calcitonin, and control group), to perform
a prospective open study for prevention of postrenal
transplantation bone loss. This study has well controlled
5 in 6 recognized risk factors of hip fracture [old age
(adjusted relative risk/RR 1.50 in 40- to 50-year-old
group, 3.27 in 55- to 70-year-old group compared with
group <40 years old), female sex (adjusted RR 1.64),
diabetic nephropathy (adjusted RR 2.96), time on dialy-
sis (adjusted RR 1.91 in patients on dialysis >12 months
compared with those <3 months), renal transplanta-
tion (adjusted RR 1.34)] identified by Ball et al among
101,039 patients with ESRD placed on the renal trans-
plant waiting list in the United States [2]. However, we
wonder if the impact of the sixth recognized risk fac-
tor, race [black (adjusted RR 0.38) and others (adjusted
RR 0.42) compared with white] [2], was also well ad-
justed in El-Agroudy’s study. In addition, although the
study showed no difference in the cumulative dose of
steroid at 1 year between groups, the possible different
effect of pulse therapy on bone loss from that of mainte-
nance therapy has never been evaluated. If it does make
a difference, the recipients receiving frequent courses
of steroid pulse therapy (2.5 g/course) should ideally
be excluded because the mean cumulative steroid dose
(1.2∼1.3 g) and patient number in groups are relatively
small.
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Renal replacement therapy
(RRT) of diabetics with
end-stage renal disease
(ESRD): Eight years’
observation from single center
in Poland
To the Editor: Van Dijk et al reported data about dia-
betic ESRD obtained from 10 European registries, omit-
ting Poland [1]. With reference to this fact we would like
to inform readers about our experiences in this field of
RRT. In the last four years we have published 3 papers
concerning RRT of diabetics [2–4]. Over the period 1992
to 2000, our dialysis center of Department and Clinic
of Internal Medicine, Diabetology and Nephrology in
Zabrze became one of the biggest centers in Poland that
conducted RRT of diabetics. During this time we dialyzed
294 patients: 59.2% of them were diabetics, 21.8% had
type 1 diabetes, and 37.4% type 2. Seventy-three percent
of diabetics were on hemodialysis and 27% were on peri-
toneal dialysis (CAPD or APD). Fifteen patients were
treated with both methods. It must be stressed that at
the start of RRT 49.7% of patients, due to late referral to
dialysis center, were critically ill, and 61.6% of them were
diabetics. We observed in consecutive years an increase
in the incidence of new diabetics with ESRD—from 4 in
1992 to 19 in 2000. The main causes of death were car-
diovascular events, which obviously occurred statistically
more frequently in diabetics. One- and five-year survival
rate was, respectively, 84.8% and 64.9% in nondiabetics
and 80.5% and 26.8% in diabetic patients. Mortality rate
was higher in patients with type 2 of diabetes; after 5 years
of RRT, 31.6% patients with type 1 diabetes were alive
and 23.2% with type 2 were alive. It was shown that di-
abetes and age over 64 years were risk factors of death.
Acute peritonitis occurred more frequently in diabetic
patients on PD in comparison to nondiabetic ones.
Increasing prevalence rate of RRT for ESRD due to
diabetes observed in our population may be explained
by the epidemic rise of type 2 diabetes. Another reason,
especially in Poland, is improved ambulatory care, more
frequent early referral of diabetics with kidney failure to
2404 Letters to the Editor
nephrologists, and easy, actually full in our region, access
to RRT.
According to our epidemiologic observations during
the last years, we have noticed, like in other countries, that
diabetic nephropathy, even taking into account diagnostic
doubts, is the leading cause of ESRD in Poland.
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